New drug targets brain inflammation in Alzheimer's
Symptom relief
Recruiting now
This study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks. Researchers will also check if it reduces brain inflammation using special brain scans. Participants must have …
Phase: PHASE2 • Sponsor: Elixiron Immunotherapeutics Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC